NCT04921358 2025-06-29
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
BeiGene
Phase 3 Terminated
BeiGene
BeiGene
Yale University
Baylor Breast Care Center
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.